Q3 EPS Forecast for Phibro Animal Health Lifted by Analyst

Phibro Animal Health Corporation (NASDAQ:PAHC) – Equities researchers at Zacks Research boosted their Q3 2026 earnings per share estimates for Phibro Animal Health in a research report issued on Wednesday, February 18th. Zacks Research analyst Team now forecasts that the company will earn $0.71 per share for the quarter, up from their prior estimate of $0.69. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.65 EPS, Q1 2027 earnings at $0.76 EPS, Q2 2027 earnings at $0.77 EPS, Q3 2027 earnings at $0.72 EPS, Q4 2027 earnings at $0.78 EPS, FY2027 earnings at $3.03 EPS, Q1 2028 earnings at $0.78 EPS, Q2 2028 earnings at $0.84 EPS and FY2028 earnings at $3.16 EPS.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS.

Several other equities research analysts have also commented on PAHC. JPMorgan Chase & Co. upped their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a report on Friday, February 6th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $37.50.

Phibro Animal Health Trading Up 1.8%

Shares of Phibro Animal Health stock opened at $52.80 on Thursday. The company’s fifty day simple moving average is $42.44 and its 200-day simple moving average is $39.95. The stock has a market capitalization of $2.14 billion, a PE ratio of 23.47, a P/E/G ratio of 0.80 and a beta of 0.80. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $56.30. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. 1620 Investment Advisors Inc. raised its position in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after buying an additional 295 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in Phibro Animal Health by 3.4% during the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after acquiring an additional 338 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Phibro Animal Health by 2.9% during the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after acquiring an additional 363 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares during the last quarter. Finally, Brooklyn Investment Group lifted its stake in Phibro Animal Health by 8.7% in the 4th quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock worth $255,000 after purchasing an additional 538 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 110,842 shares of the stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the sale, the chief executive officer owned 122,958 shares in the company, valued at approximately $5,948,708.04. This trade represents a 47.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 293,920 shares of company stock valued at $13,833,025 over the last three months. Corporate insiders own 50.13% of the company’s stock.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s payout ratio is presently 21.33%.

Phibro Animal Health News Summary

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks added PAHC to multiple Rank #1 (Strong Buy) lists — including momentum and value screens — which can attract short-term momentum traders and systematic buy programs. Best Momentum Stocks to Buy for February 20th New Strong Buy Stocks for February 20th Best Value Stocks to Buy for February 20th
• Positive Sentiment: Analyst models moved higher: Zacks Research has repeatedly raised quarterly and full‑year EPS forecasts (FY2026 to $2.96 from $2.73 and upgrades to FY2027/FY2028 estimates), signaling improved earnings visibility after the company’s February quarter beat and FY2026 guidance. That fundamental re-rating supports higher multiples. MarketBeat PAHC coverage
• Positive Sentiment: Recent fundamentals: Phibro beat Q4/quarterly estimates and gave FY2026 EPS guidance (2.93–3.10), and it declared a modest quarterly dividend — all supportive to investor confidence and institutional interest. MarketBeat PAHC coverage
• Neutral Sentiment: A Yahoo Finance piece flags valuation after the recent run — helpful context for investors assessing whether current gains are driven by fundamentals or short‑term momentum. It suggests caution on stretch valuations even as momentum persists. Assessing Phibro Animal Health (PAHC) Valuation After Strong Share Price Momentum
• Neutral Sentiment: Analyst mix remains mixed: despite estimate lifts, coverage is varied (several Holds, a few Buys and one Sell per MarketBeat), so upside depends on continued execution vs. elevated expectations. MarketBeat PAHC coverage
• Negative Sentiment: Insider selling: CEO Jack Bendheim has sold multiple sizable blocks in February (recent disclosures show several transactions at ~\$51–\$52), which some investors view as a negative signal on near‑term insider conviction. That selling can cap enthusiasm despite the other positives. Phibro Animal Health (NASDAQ:PAHC) CEO Sells $361,856.00 in Stock

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.